<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="Generator" content="Microsoft Word 14 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:"Fira Sans";}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Times New Roman","serif";
color:#0000CC;
font-weight:normal;
font-style:normal;
text-decoration:none none;}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1110970309;
mso-list-template-ids:1218336542;}
@list l1
{mso-list-id:1474787526;
mso-list-template-ids:361167454;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="blue" vlink="purple">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;color:#0000CC"><a href="http://www.independent.co.uk/news/uk/politics/antibiotic-resistance-could-become-bigger-threat-to-mankind-than-cancer-a6983611.html">http://www.independent.co.uk/news/uk/politics/antibiotic-resistance-could-become-bigger-threat-to-mankind-than-cancer-a6983611.html</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;color:#0000CC"><o:p> </o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><b><span style="font-size:24.0pt;font-family:"Fira Sans";color:#281E1E">Antibiotic resistance 'could become bigger threat to mankind than cancer'<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">George Osborne says the cost of doing nothing is 'too great'
<o:p></o:p></span></p>
<table class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0">
<tbody>
<tr>
<td nowrap="" style="padding:0in 0in 0in 0in">
<p class="MsoNormal" style="vertical-align:top"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E"><o:p> </o:p></span></p>
</td>
<td nowrap="" style="padding:0in 0in 0in 0in">
<p class="MsoNormal" style="vertical-align:top"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E"><o:p> </o:p></span></p>
</td>
<td nowrap="" style="padding:0in 0in 0in 0in">
<p class="MsoNormal" style="vertical-align:top"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E"><o:p> </o:p></span></p>
</td>
<td nowrap="" style="padding:0in 0in 0in 0in">
<p class="MsoNormal" style="vertical-align:top"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E"><o:p> </o:p></span></p>
</td>
<td nowrap="" style="padding:0in 0in 0in 0in">
<p class="MsoNormal" style="vertical-align:top"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E"><o:p> </o:p></span></p>
</td>
</tr>
</tbody>
</table>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E"><img border="0" width="457" height="401" id="Picture_x0020_6" src="cid:image001.jpg@01D19631.39FCD590" alt="Antibiotics.jpg"></span><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">It
is thought 10 million people a year could die globally by 2050 Getty <o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">Resistance to antibiotics will become "an even greater threat to mankind than cancer" without global action,
Chancellor George Osborne will warn today.<o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">The latest evidence suggests 10 million people a year could die globally by 2050, as a result of antibiotics
becoming powerless against common infections - more than currently die from cancer, he will say.<o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">The Chancellor will tell delegates at the International Monetary Fund (IMF) meeting in Washington that there
will be an "enormous economic cost" too: by 2050, antimicrobial resistance could reduce global GDP by up to 3.5% - a cumulative cost of 100 trillion US dollars (£70 trillion).<o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">He will say: "Unless we take global action, antimicrobial resistance will become an even greater threat to mankind
than cancer currently is. <o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">"It is not just a health problem but an economic one, too. The cost of doing nothing, both in terms of lives
lost and money wasted, is too great, and the world needs to come together to agree a common approach.<o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">"We have to dramatically shift incentives for pharmaceutical companies and others to create a long-term solution
to this problem, with new rewards, funded globally, that support the development of new antibiotics and ensure access to antibiotics in the developing world.<o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">"To achieve a long-term solution we also need better rapid diagnostics that will cut the vast amounts of unnecessary
antibiotic use."<o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E">In 2014 the PM was the first G20 leader to speak out publicly about the magnitude of the threat, and asked the
Treasury minister and economist Lord O'Neill to come up with potential solutions to the growing global problem of drug-resistant infections.<o:p></o:p></span></p>
<p><span style="font-family:"Fira Sans";color:#281E1E">The UK has implemented two of his initial recommendations: to increase Government funding for early stage research and to help build capabilities in low-income settings to monitor the development and spread
of drug resistance.<o:p></o:p></span></p>
<p><span style="font-family:"Fira Sans";color:#281E1E">The Chancellor is expected to back a proposal from Lord O'Neill and others to create "market entry rewards" which will pay a large prize to a pharmaceutical company, or set of companies, that get a new
antibiotic or diagnostic to market.<o:p></o:p></span></p>
<p><span style="font-family:"Fira Sans";color:#281E1E">Lord O'Neill will publish the final recommendations from his review in May. <o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto"><span style="font-size:12.0pt;font-family:"Fira Sans";color:#281E1E"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;color:#0000CC"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;color:#0000CC"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:9.0pt;color:#000099">Deborah L. DeBiasi<br>
<b>Email: <a href="mailto:Deborah.DeBiasi@deq.virginia.gov"><span style="color:#000099">Deborah.DeBiasi@deq.virginia.gov</span></a><i><br>
</i></b>WEB site address: <a href="http://www.deq.virginia.gov/"><span style="color:#000099">www.deq.virginia.gov</span></a><br>
Virginia Department of Environmental Quality<br>
Office of Water Permits <br>
Industrial Pretreatment/Whole Effluent Toxicity (WET) Program<br>
PPCPs, EDCs, and Microconstituents<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:9.0pt;color:#000099"><a href="http://www.deq.virginia.gov/Programs/Water/PermittingCompliance/PollutionDischargeElimination/Microconstituents.aspx"><span style="color:#000099">http://www.deq.virginia.gov/Programs/Water/PermittingCompliance/PollutionDischargeElimination/Microconstituents.aspx</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:9.0pt;color:#000099">Mail: P.O. Box 1105, Richmond, VA 23218<br>
Location: 629 E. Main Street, Richmond, VA 23219<br>
PH: 804-698-4028 FAX: 804-698-4032</span><span style="font-size:9.0pt;color:navy"><o:p></o:p></span></p>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>